Chugai Pharmaceutical Operating Income 2020-2025 | CHGCY

Chugai Pharmaceutical operating income for the twelve months ending March 31, 2025 was $2.318B, a 19.39% decline year-over-year.

  • Chugai Pharmaceutical annual operating income for 2024 was $3.577B, a 14.72% increase from 2023.
  • Chugai Pharmaceutical annual operating income for 2023 was $3.118B, a 24.07% decline from 2022.
  • Chugai Pharmaceutical annual operating income for 2022 was $4.106B, a 6.96% increase from 2021.

Chugai Pharmaceutical Operating Income 2020-2025 | CHGCY

  • Chugai Pharmaceutical annual operating income for 2024 was $3.577B, a 14.72% increase from 2023.
  • Chugai Pharmaceutical annual operating income for 2023 was $3.118B, a 24.07% decline from 2022.
  • Chugai Pharmaceutical annual operating income for 2022 was $4.106B, a 6.96% increase from 2021.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$66.3B
Daiichi Sankyo, - (DSNKY)$46.4B
Takeda Pharmaceutical (TAK)$43.3B
BeOne Medicines - (ONC)$32.9B
Sandoz Group AG (SDZNY)$25.9B
Summit Therapeutics (SMMT)$19.8B
Merck (MKKGY)$16.5B
Shionogi (SGIOY)$14.3B
Neurocrine Biosciences (NBIX)$13.5B
United Therapeutics (UTHR)$12.7B
Orion OYJ (ORINY)$11.5B
IPSEN (IPSEY)$10.8B
Stevanato Group S.p.A (STVN)$7.6B
Grifols, S.A (GRFS)$7.5B
Corcept Therapeutics (CORT)$7.4B
Ionis Pharmaceuticals (IONS)$6.9B
Madrigal Pharmaceuticals (MDGL)$6.4B
Hikma Pharmaceuticals Plc (HKMPF)$5.9B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.3B
Hypermarcas (HYPMY)$3.1B
Crinetics Pharmaceuticals (CRNX)$2.7B
Catalyst Pharmaceuticals (CPRX)$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
NewAmsterdam Pharma (NAMS)$2.5B
Centessa Pharmaceuticals (CNTA)$2.2B
Ocular Therapeutix (OCUL)$1.9B
Endo (NDOI)$1.8B
ARS Pharmaceuticals (SPRY)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.7B